Reviewed by Michael Gill, B. Sc.
25 Pulmonary Fibrosis Clinical Trials Near Me
Top Hospitals for Pulmonary Fibrosis Clinical Trials
Image of University of Kansas Medical Center in Kansas.
University of Kansas Medical Center
Kansas City
8Active Trials
15All Time Trials for Pulmonary Fibrosis
2013First Pulmonary Fibrosis Trial
Image of Vanderbilt University Medical Center in Tennessee.
Vanderbilt University Medical Center
Nashville
8Active Trials
27All Time Trials for Pulmonary Fibrosis
2003First Pulmonary Fibrosis Trial
Pulmonary Fibrosis Clinical Trials by Phase of Trial
Top Treatments for Pulmonary Fibrosis Clinical Trials
Treatment Name
Active Pulmonary Fibrosis Clinical Trials
All Time Trials for Pulmonary Fibrosis
First Recorded Pulmonary Fibrosis Trial
PRM-151
2
4
2011
Inhaled Treprostinil
2
5
2016
PLN-74809
2
3
2019
EV-Pure™ and WJ-Pure™ plus standard care
1
1
2022
68Ga-FAPi-46
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Pulmonary Fibrosis
Treatment
Year
Sponsor
TRK-250
2018
Toray Industries, Inc
Epigallocatechin-3-gallate (EGCG)
2018
University of California, San Francisco
ND-L02-s0201
2018
Nitto Denko Corporation
VAY736
2017
Novartis Pharmaceuticals
CC-90001
2017
Celgene

What Are Pulmonary Fibrosis Clinical Trials?

Pulmonary Fibrosis is a group of over 200 lung diseases that cause the lung tissues to become damaged and scarred. The scarred lung tissues thicken over time, making normal breathing difficult for the patient.

Pulmonary Fibrosis clinical trials are conducted to better understand the condition, individual diseases, and potential treatments that are both safe and effective and don’t negatively interact with other treatments or trigger other conditions.

Why Is Pulmonary Fibrosis Being Studied Through Clinical Trials?

Pulmonary Fibrosis clinical trials help researchers and medical professionals understand the disease and its treatment better. These trials are also conducted to determine which treatments are effective for which types of Pulmonary Fibrosis and which drugs may have potential side effects. These trials are conducted on Pulmonary Fibrosis patients and cover an extensive range of treatments/drugs, from Chinese herbal medicine to novel drugs.

Pulmonary Fibrosis clinical trials also cover topics like early detection, diagnostic processes, and its interaction with events like pregnancies.

What Are The Types of Treatments Available For Pulmonary Fibrosis?

The treatments offered to Pulmonary Fibrosis patients vary based on the severity of the disease and the tolerance potential of the patient. There are four common treatments for Pulmonary Fibrosis.

For many patients, Pulmonary rehabilitation can lead to some significant improvements. The idea behind this type of treatment is to prepare the body to better handle the adverse symptoms associated with the disease.

There are multiple drugs/medications that have shown promising results in reducing the scarring of the lungs and slowing down the symptoms associated with thickening lung muscles. Two drugs are approved by the FDA for the treatment and are generally considered safe.

A lot of patients need oxygen therapy to better manage their condition. It doesn’t _treat _the condition itself, but it offers relief to the patient and ensures that an adequate amount of oxygen is reaching the body.

A lung transplant, if the recipient's body properly accepts the new lungs, can offer complete relief to Pulmonary Fibrosis patients. But the procedure itself is complicated, and the risks are relatively higher compared to other treatments.

What Are Some Recent Breakthrough Clinical Trials For Pulmonary Fibrosis?

2019: Long-term Treatment Of Pulmonary Fibrosis with PRM-151 - PRM-151 is a recombinant human pentraxin 2 protein that has shown promising results in a clinical trial including 111 patients. Seventy-four were given the protein over a period of 28 weeks, and it was found to be quite well-tolerated.

2022: Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis - An inhibitor, BI 1015550, has been tested in a phase-2 clinical trial with a placebo control in place. One hundred forty-seven people were randomly selected and assigned the inhibitor or the placebo. The inhibitor showed promising results though there were consistent adverse effects for a small percentage of the sample group. It has been granted FDA breakthrough therapy status.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Pulmonary Fibrosis Clinical Trial Research?

Pulmonary Fibrosis Foundation - The foundation is dedicated to treatments and, ideally, a cure for Pulmonary Fibrosis. It has been involved in over 100 clinical trials on Pulmonary Fibrosis, representing more than 12% of all known clinical trials.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26. https://pubmed.ncbi.nlm.nih.gov/321056322 Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3. https://pubmed.ncbi.nlm.nih.gov/320155073 Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese. https://pubmed.ncbi.nlm.nih.gov/320648534 Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese. https://pubmed.ncbi.nlm.nih.gov/320648535 Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NA, McCormack DG, Parraga G. Hyperpolarized 129Xe magnetic resonance imaging: tolerability in healthy volunteers and subjects with pulmonary disease. Acad Radiol. 2012 Aug;19(8):941-51. doi: 10.1016/j.acra.2012.03.018. Epub 2012 May 15. https://pubmed.ncbi.nlm.nih.gov/225917246 Montesi SB, Izquierdo-Garcia D, Désogère P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. https://pubmed.ncbi.nlm.nih.gov/311617707 Désogère P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384). pii: eaaf4696. doi: 10.1126/scitranslmed.aaf4696. https://pubmed.ncbi.nlm.nih.gov/283815378 Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. Acad Radiol. 2012 Feb;19(2):141-52. doi: 10.1016/j.acra.2011.10.007. Epub 2011 Nov 21. https://pubmed.ncbi.nlm.nih.gov/221042889 Rebelo AL, Chevalier MT, Russo L, Pandit A. Role and therapeutic implications of protein glycosylation in neuroinflammation. Trends Mol Med. 2022 Apr;28(4):270-289. doi: 10.1016/j.molmed.2022.01.004. Epub 2022 Feb 1. Review. https://pubmed.ncbi.nlm.nih.gov/3512083610 Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med. 2004 Jan 12;164(1):83-91. https://pubmed.ncbi.nlm.nih.gov/14718327